Clinical Trial

Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes

Study acronym: PREVENT-SIH
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Steroid injections used to treat painful joints can temporarily increase glucose levels in people with type 2 diabetes. This study will test whether a short course of pre-emptive neutral protamine Hagedorn, NPH, insulin can reduce high glucose after a standard corticosteroid injection into the knee. Adults with type 2 diabetes who are scheduled to receive one intra-articular injection of triamcinolone acetonide 40 mg for knee osteoarthritis will be randomly assigned to one of two groups. The experimental group will receive a prespecified NPH insulin regimen beginning immediately after the injection and continuing for three doses. The comparison group will continue usual reactive diabetes management without pre-emptive NPH insulin. Both groups will use blinded continuous glucose monitoring and scheduled capillary glucose testing. The main outcome is the percentage of continuous glucose monitoring time above 180 mg/dL during the first 72 hours after the corticosteroid injection. Hypoglycaemia, rescue treatment, healthcare contacts, treatment burden, acceptability and adverse events will also be assessed.
Trial Details
NCT Number NCT07757464
Lead Sponsor Shifa International Hospital
Collaborators: Al Ain University
Conditions Diabetes Mellitus, Type 2, Hyperglycemia Due to Type 2 Diabetes Mellitus, Osteoarthritis, Knee
Enrollment 125 participants
Start Date 2026-08-10
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11